Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,074
  • Shares Outstanding, K 13,550
  • Annual Sales, $ 10 K
  • Annual Income, $ -23,390 K
  • 36-Month Beta 5.53
  • Price/Sales 25,481.52
  • Price/Cash Flow 0.00
  • Price/Book 2.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.09 +52.70%
on 10/18/17
14.05 -1.21%
on 11/17/17
+4.56 (+48.93%)
since 10/17/17
3-Month
5.62 +146.98%
on 08/23/17
14.05 -1.21%
on 11/17/17
+7.56 (+119.62%)
since 08/17/17
52-Week
5.42 +156.09%
on 08/14/17
25.95 -46.51%
on 04/13/17
-1.85 (-11.76%)
since 11/17/16

Most Recent Stories

More News
Innovation Drives Value for Leading Cannabis Biotechs

The medicinal cannabis market is expected to reach almost US$56 billion by 2025, according to a report by Grand View Research (http://nnw.fm/rXx0Z), driven in part by demand for therapeutic applications...

IMLFF : 0.5460 (+3.33%)
CARA : 12.18 (-0.25%)
GWPH : 115.88 (-1.42%)
INSY : 5.37 (+1.51%)
ZYNE : 13.88 (+5.47%)
IN.CN : 0.700 (+7.69%)
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments,...

ZYNE : 13.88 (+5.47%)
Biotech M&A Momentum Attractive for Cannabinoid R&D Space

NEW YORK, November 7, 2017 /PRNewswire/ --

FOLD : 13.11 (-2.74%)
IMLFF : 0.5460 (+3.33%)
AXIM : 6.6500 (+3.10%)
MS : 48.70 (+0.21%)
GWPH : 115.88 (-1.42%)
ZYNE : 13.88 (+5.47%)
IN.CN : 0.700 (+7.69%)
Biotech M&A Momentum Attractive for Cannabinoid R&D Space

Morgan Stanley's research team in January 2017 forecast that biotech-pharmaceutical companies - with a combined $75 billion in cash on hand - would strategize to boost revenue growth through mergers and...

FOLD : 13.11 (-2.74%)
IMLFF : 0.5460 (+3.33%)
AXIM : 6.6500 (+3.10%)
MS : 48.70 (+0.21%)
GWPH : 115.88 (-1.42%)
ZYNE : 13.88 (+5.47%)
IN.CN : 0.700 (+7.69%)
Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments,...

ZYNE : 13.88 (+5.47%)
Data Shows Sales of Legal Cannabis Products Remain Strong

New data published by Verify Markets, states that the wholesale legal cannabis market in the U.S was valued at $210.7 million in 2016. The increased legalization efforts in the November 2016 elections...

CBDS : 3.0000 (+2.74%)
CRBP : 7.00 (-0.71%)
CARA : 12.18 (-0.25%)
ZYNE : 13.88 (+5.47%)
KWFLF : 0.7793 (-1.19%)
Economic Impact of Biosynthesis on the Cannabis Industry

NEW YORK, October 31, 2017 /PRNewswire/ --

ACB.TO : 5.51 (+2.04%)
IMLFF : 0.5460 (+3.33%)
ACBFF : 4.3397 (+2.23%)
WEED.TO : 18.45 (+6.89%)
GWPH : 115.88 (-1.42%)
ZYNE : 13.88 (+5.47%)
IN.CN : 0.700 (+7.69%)
Economic Impact of Biosynthesis on the Cannabis Industry

According to a recent Haywood Securities research report, the value of the cannabidiol (CBD) market is expected to hit $2.1 billion by 2020. CBD is just one compound out of more than 90 found within the...

ACB.TO : 5.51 (+2.04%)
IMLFF : 0.5460 (+3.33%)
ACBFF : 4.3397 (+2.23%)
WEED.TO : 18.45 (+6.89%)
GWPH : 115.88 (-1.42%)
ZYNE : 13.88 (+5.47%)
IN.CN : 0.700 (+7.69%)
TWMJF : 14.4500 (+6.88%)
Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma, and Collegium Pharma

If you want a Stock Review on ADMS, NEOS, ZYNE, or COLL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pre-market today, DailyStockTracker.com observes...

COLL : 17.14 (+1.90%)
ADMS : 28.41 (+2.60%)
ZYNE : 13.88 (+5.47%)
NEOS : 10.15 (-3.33%)
Innovative Biotechnology Companies are Transforming Cannabis-based Medical Products

NEW YORK, October 26, 2017 /PRNewswire/ --

ACB.TO : 5.51 (+2.04%)
IMLFF : 0.5460 (+3.33%)
ACBFF : 4.3397 (+2.23%)
WEED.TO : 18.45 (+6.89%)
GWPH : 115.88 (-1.42%)
ZYNE : 13.88 (+5.47%)
IN.CN : 0.700 (+7.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 14.63
1st Resistance Point 14.26
Last Price 13.88
1st Support Level 13.30
2nd Support Level 12.71

See More

52-Week High 25.95
Fibonacci 61.8% 18.11
Fibonacci 50% 15.69
Last Price 13.88
Fibonacci 38.2% 13.26
52-Week Low 5.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart